Market Overview:
The global precision cancer therapies market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, technological advancements in precision cancer therapies, and rising demand for targeted therapies. The global precision cancer therapies market is segmented on the basis of type into hormone therapy, immunotherapies, targeted therapy, monoclonal antibody therapy, and gene therapy. The hormone therapy segment is expected to account for the largest share of the global precision cancer therapies market in 2018. This segment is expected to grow at a CAGR of 11% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to rising demand for hormonal treatments for various types of cancers and increasing awareness about these treatments among patients and healthcare professionals.
Product Definition:
Precision cancer therapies are treatments that are specifically designed to kill cancer cells while minimizing damage to healthy cells. They can be used as standalone therapies or in combination with other treatments. The importance of precision cancer therapies is that they can provide more targeted and effective treatment for patients, resulting in improved outcomes and fewer side effects.
Hormone Therapy:
Hormone therapy is a medical treatment for cancer that involves the administration of hormones by vein, oral or by injection. Hormone therapy can be used with chemotherapy and radiation therapies to enhance their effect. The aim of hormone therapy is to reduce the size or stop the growth of tumors in patients with breast, prostate or other types of cancer.
The global market for hormone therapies was valued at USD 19 billion in 2015.
Immunotherapies:
Precision cancer therapies are the new wave of treatments that involve very specific and personalized medicine for patients with cancer. Precision cancer therapies include immunotherapies, biologic response modifiers, monoclonal antibodies, and small molecule tyrosine kinase inhibitors. Immunotherapies are the most prominent type of precision therapy as it involves a patient’s immune system to fight against their tumor.
Application Insights:
The market is segmented by application into hospitals, diagnostic centers, oncology clinics and research institutes. The hospitals segment dominated the overall industry in terms of revenue in 2017 owing to a large patient base that requires cancer treatment and increasing government funding for the development of advanced healthcare facilities.
Immunotherapy is anticipated to be one of the fastest-growing segments over the forecast period due to its ability to stimulate an immune response against tumor cells. This therapy involves administration of immunotherapies such as monoclonal antibodies (mAb), which are highly effective in treating cancers with fewer side effects compared with other therapies such as chemotherapy or radiotherapy. Precision immunotherapies enable patients suffering from chronic diseases related to lymphoid malignancies or blood disorders at high risk for developing these diseases due to genetic abnormalities including chromosomal translocation that cannot be treated through regular medication alone.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, availability of novel therapies, high healthcare expenditure and government support for cancer research & development. Moreover, increasing R&D activities by major companies is also expected to contribute towards growth during the forecast period. Asia Pacific is estimated to witness lucrative CAGR over the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in awareness about precision cancer therapies among patients will drive regional growth during the forecast period (2018-2030). In addition, a rise in investment by various organizations for developing oncology pipeline will further fuel revenue generation prospects across this region over next eight years (2018-2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for precision cancer therapies market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to this disease. This number is expected to increase by 70% over the next two decades, making it one of the leading causes of death worldwide. This high prevalence rate is driving demand for better and more targeted therapies, which is benefiting the precision cancer therapies market.
- Advances in technology: The advances in technology are another key growth driver for this market as they are helping researchers develop novel and more effective precision cancer therapies. For instance, recent advances in gene sequencing technologies have allowed researchers to identify specific genetic mutations that drive tumor growth, thus paving way for development of personalized treatments specifically targeting these mutations. Such technological advancements are helping fuel demand for precision cancer therapies and are thus aiding in expansion of this market globally..
Scope Of The Report
Report Attributes
Report Details
Report Title
Precision Cancer Therapies Market Research Report
By Type
Hormone Therapy, Immunotherapies, Targeted Therapy, Monoclonal Antibody Therapy, Gene Therapy
By Application
Hospitals, Diagnostic Centers, Oncology Clinics, Research Institutes
By Companies
Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
150
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Precision Cancer Therapies Market Report Segments:
The global Precision Cancer Therapies market is segmented on the basis of:
Types
Hormone Therapy, Immunotherapies, Targeted Therapy, Monoclonal Antibody Therapy, Gene Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Diagnostic Centers, Oncology Clinics, Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Bayer HealthCare
- GlaxoSmithKline
- OncoGenex Pharmaceuticals
- Hospira
- Boehringer Ingelheim
- AstraZeneca
- Aveo Pharmaceuticals
Highlights of The Precision Cancer Therapies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hormone Therapy
- Immunotherapies
- Targeted Therapy
- Monoclonal Antibody Therapy
- Gene Therapy
- By Application:
- Hospitals
- Diagnostic Centers
- Oncology Clinics
- Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Precision Cancer Therapies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Precision Cancer Therapies is a clinical-stage biotechnology company focused on the development of novel targeted cancer therapies. The company's lead product candidate, PRX-101, is an investigational checkpoint inhibitor that has demonstrated activity against various types of cancer.
Some of the key players operating in the precision cancer therapies market are Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals.
The precision cancer therapies market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Precision Cancer Therapies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Precision Cancer Therapies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Precision Cancer Therapies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Precision Cancer Therapies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Precision Cancer Therapies Market Size & Forecast, 2020-2028
4.5.1 Precision Cancer Therapies Market Size and Y-o-Y Growth
4.5.2 Precision Cancer Therapies Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Hormone Therapy
5.2.2 Immunotherapies
5.2.3 Targeted Therapy
5.2.4 Monoclonal Antibody Therapy
5.2.5 Gene Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Diagnostic Centers
6.2.3 Oncology Clinics
6.2.4 Research Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Precision Cancer Therapies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Precision Cancer Therapies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Hormone Therapy
9.6.2 Immunotherapies
9.6.3 Targeted Therapy
9.6.4 Monoclonal Antibody Therapy
9.6.5 Gene Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Diagnostic Centers
9.10.3 Oncology Clinics
9.10.4 Research Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Hormone Therapy
10.6.2 Immunotherapies
10.6.3 Targeted Therapy
10.6.4 Monoclonal Antibody Therapy
10.6.5 Gene Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Diagnostic Centers
10.10.3 Oncology Clinics
10.10.4 Research Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Hormone Therapy
11.6.2 Immunotherapies
11.6.3 Targeted Therapy
11.6.4 Monoclonal Antibody Therapy
11.6.5 Gene Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Diagnostic Centers
11.10.3 Oncology Clinics
11.10.4 Research Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Hormone Therapy
12.6.2 Immunotherapies
12.6.3 Targeted Therapy
12.6.4 Monoclonal Antibody Therapy
12.6.5 Gene Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Diagnostic Centers
12.10.3 Oncology Clinics
12.10.4 Research Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Hormone Therapy
13.6.2 Immunotherapies
13.6.3 Targeted Therapy
13.6.4 Monoclonal Antibody Therapy
13.6.5 Gene Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Diagnostic Centers
13.10.3 Oncology Clinics
13.10.4 Research Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Precision Cancer Therapies Market: Competitive Dashboard
14.2 Global Precision Cancer Therapies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Bayer HealthCare
14.3.3 GlaxoSmithKline
14.3.4 OncoGenex Pharmaceuticals
14.3.5 Hospira
14.3.6 Boehringer Ingelheim
14.3.7 AstraZeneca
14.3.8 Aveo Pharmaceuticals
